Digest preview

Fennec Pharmaceuticals
Weekly company brief · Sep 12, 2026 – Oct 12, 2026

At a glance
Observed headcount: 59, +1 (+1.7%) from 58 on Sep 12, 2026 to Oct 12, 2026.
2 new job postings first seen in the period.
0 inferred departures among 40 tracked employees. 32 of 40 had a successful workforce observation in the past seven days.

Analyst read
AI analysis could not be generated for this edition. The collected facts below are unchanged.

Headcount
Observed headcount: 59, +1 (+1.7%) from 58 on Sep 12, 2026 to Oct 12, 2026.

New job postings (2 of 2 shown)
Key Account Director · Southeast · first seen Sep 30, 2026
M A R K E T A C C E S S - O N C O L O G Y KEY ACCOUNT DIRECTOR (SOUTHEAST) ABOUT FENNEC CONTACT United States (Southeast- Florida, Puerto Rico, Georgia & Carolinas) resumes@fennecpharma.com www.fennecpharma.com NOW HIRING Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum- induced ototoxicity in pediatric patients.
Vice President, Pharmacovigilance & Regulatory Affairs · Location unavailable · first seen Sep 21, 2026
NOW HIRING POSITION SUMMARY ABOUT FENNEC www.fennecpharma.com U N I T E D S T A T E S - O N C O L O G Y VICE PRESIDENT, PHARMACOVIGILANCE & REGULATORY AFFAIRS The Vice President, Pharmacovigilance & Regulatory Affairs leads the company’s global pharmacovigilance, medical safety, and regulatory activities across the product lifecycle.

People
0 inferred departures among 40 tracked employees. 32 of 40 had a successful workforce observation in the past seven days.

Coverage notes
Headcount reflects provider observations. Posting dates are first-seen dates; openings do not establish net hiring. Job descriptions, when shown, are source excerpts.

Review company evidence: https://workforce-signals.nickmattiacci.com/companies/fennec-pharmaceuticals